- Conditions
- Stage IV Melanoma
- Interventions
- volociximab
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • La Jolla, California • Aurora, Colorado + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 937–960
of 17,257
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myelodysplastic Syndromes, Multiple Myeloma, Anemia
- Interventions
- INCB000928
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Miami, Florida • Sarasota, Florida + 5 more
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
- Interventions
- Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Ziv-Aflibercept
- Radiation · Other · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
- Interventions
- 170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Maridebart cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 53 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Genomic and Proteomic Profiling
- Other
- Lead sponsor
- Sanford Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- celecoxib, temozolomide, thalidomide, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- Sleep Disturbances Associated With Menopause
- Interventions
- Elinzanetant, Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 22
- States / cities
- Little Port Walter, Alaska • Scottsdale, Arizona • Encinitas, California + 17 more
- Conditions
- Diabetes Mellitus, Type 1, Overweight and Obesity
- Interventions
- Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 19 Years to 30 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Chapel Hill, North Carolina
- Conditions
- Chronic Low Back Pain
- Interventions
- hydrocodone/acetaminophen extended release, Placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Anaheim, California • Burbank, California + 14 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
- Interventions
- Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
- Radiation · Drug
- Lead sponsor
- Benjamin Spieler
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Burns, Insulin Resistance
- Interventions
- fenofibrate
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Drug · Biological
- Lead sponsor
- Sawa Ito, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
- Interventions
- ZB131
- Drug
- Lead sponsor
- ZielBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 6 more
- Conditions
- Lymphoma
- Interventions
- aldesleukin, recombinant human stem cell factor
- Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Columbus, Ohio
- Conditions
- Solid Tumors
- Interventions
- nesvacumab (REGN910/ SAR307746)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- San Francisco, California • San Antonio, Texas
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome
- Interventions
- PD 0299685 at 15mg BID, PD 0299685 at 30mg BID, placebo for PD 0299685
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more
- Conditions
- Breast Cancer, Metastasis
- Interventions
- GPX-100 (13-deoxydoxorubicin)
- Drug
- Lead sponsor
- Gem Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Rheumatoid Arthritis
- Interventions
- LY2439821, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 37
- States / cities
- Peoria, Arizona • La Mesa, California • Palm Desert, California + 34 more
- Conditions
- Metastatic Melanoma
- Interventions
- DC vaccine, Dasatinib
- Biological · Drug
- Lead sponsor
- Walter J. Storkus
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Obesity, Overweight
- Interventions
- BI 3034701, Placebo matching BI 3034701
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • West Hills, California • Miami, Florida + 16 more
- Conditions
- Gait Disorders, Neurologic
- Interventions
- droxidopa
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 30 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- West Bloomfield, Michigan
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- ABT-089, Placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 23
- States / cities
- Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more